Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence

D. Hawksworth, L. Ravindranath, Y. Chen, B. Furusato, I. A. Sesterhenn, D. G. Mcleod, S. Srivastava, G. Petrovics*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

133 Scopus citations


Alterations of chromosome 8, including amplification at 8q24 harboring the C-MYC oncogene, have been noted as one of the most common chromosomal abnormalities in prostate cancer (CaP) progression. However, the frequency of C-MYC alterations in CaP has remained uncertain. A recent study, using a new anti-MYC antibody, described prevalent upregulation of nuclear C-MYC protein expression as an early oncogenic alteration in CaP. Further, we have recently reported regulation of C-MYC expression by ERG and a significant correlation between C-MYC overexpression and TMPRSS2-ERG fusion in early stage CaP. These emerging data suggest that increased C-MYC expression may be a critical and early oncogenic event driving CaP progression. In this study, we assessed whether C-MYC mRNA overexpression in primary prostate tumors was predictive of more aggressive tumor or disease progression. Our approach was to quantitatively determine C-MYC mRNA expression levels in laser capture micro-dissected tumor cells and matched benign epithelial cells in a radical prostatectomy cohort with long follow-up data available. On the basis of our results, we conclude that elevated C-MYC expression in primary prostate tumor is biologically relevant and may be a predictor of future biochemical recurrence.

Original languageEnglish
Pages (from-to)311-315
Number of pages5
JournalProstate Cancer and Prostatic Diseases
Issue number4
StatePublished - Dec 2010
Externally publishedYes


  • C-MYC oncogene
  • quantitative expression
  • recurrence


Dive into the research topics of 'Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence'. Together they form a unique fingerprint.

Cite this